## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

**Reporting Owners** 

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Responses	s)												
1. Name and Address of Reporting Person* RABBANI ELAZAR				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X_Director  10% Owner				
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 11/16/2011						X Officer (give title below) Other (specify below)  CEO and Secretary				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)					ar)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
NEW YORK,, NY 10022								Form filed by More than One Reporting Person						
(City	)	(State)	(Zip)	Т	able I - No	n-De	erivative S	Securiti	ies Acqui	red, Disp	osed of, or l	Beneficially	Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			(A) or D (Instr. 3,	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or (A) or (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, par value \$0.01 per share		11/16/2011		P	·	600	A	\$ 2.275	2,100,889 (1)			D		
Common Stock, par value \$0.01 per share		11/16/2011		P		6,600	A	\$ 2.28	2,107,489 (1)			D		
Common Stock, par value \$0.01 per share		11/16/2011		P		5,700	A	\$ 2.285	2,113,189 (1)		D			
Common Stock, par value \$0.01 per share		11/16/2011		P		3,600	A	\$ 2.29	2,116,789 (1)			D		
Common Stock, par value \$0.01 per share		11/16/2011		P		2,800	A	\$ 2.295	2,119,589 (1)			D		
Common Stock, par value \$0.01 per share		11/16/2011		P		100	A	\$ 2.2968	2,119,689 (1)			D		
Common Stock, par value \$0.01 per share		11/16/2011		P		600	A	\$ 2.3	2,120,2	89 (1)		D		
Reminder:	Report on a s	eparate line f	or each class of secu	rities beneficially o	wned direc	Per	sons wh	o resp	form are	not requ		formation spond unle trol numbe	ss	1474 (9-02)
				Derivative Securit (e.g., puts, calls, w						y Owned				
Derivative Conversion Da		3. Transactic Date (Month/Day	Year) Execution Da	4. Transaction Code (Instr. 8) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		and (M	and Expiration Date (Month/Day/Year) A U Si		Amo Unde Secu	ount of derlying urities str. 3 and Derivative Security (Instr. 5)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form o Derivat Security Direct ( or Indir	Ownersh (Instr. 4) D) ect
				Code V	(A) (D)		te ercisable	Expirat Date	Title	Amount or Number of Shares				

Relationships

Reporting Owner Name / Address	Director	10% Owner	Officer	Other
RABBANI ELAZAR C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK,, NY 10022	X		CEO and Secretary	

### **Signatures**

/s/ Elazar Rabbani	11/18/2011
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Includes (i) 239,000 shares of Common Stock issuable upon the exercise of options which are exercisable within 60 days from the date hereof, (ii) 5,547 shares of Common Stock held in the name of the Reporting Person as custodian for certain of his children, (iii) 22,115 shares of Common Stock held in the name of the Reporting Person's wife as custodian for certain of their children, (iv) an aggregate of 5,100 shares of Common Stock held in the name of the Reporting Person's children and (v) 12,502 shares of Common Stock held in the Company's 401(k) plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.